NCT04470908View on ClinicalTrials.gov

The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

November 10, 2020

Study Completion Date

November 10, 2020

Conditions
HealthyMale
Interventions
DRUG

Zanubrutinib

Single oral dose of 320 mg

DRUG

Rifabutin

Oral dose of 300 mg once daily

Trial Locations (1)

32117

Covance Clinical Research Unit, Daytona Beach

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT04470908 - The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males | Biotech Hunter | Biotech Hunter